Literature DB >> 1991673

Acute and chronic efficacy of felodipine in congestive heart failure.

P Agostoni1, E Doria, S Riva, A Polese.   

Abstract

In 13 patients with congestive heart failure we tested the acute hemodynamic effects of 5 vs. 10 mg felodipine tablets, in a double-blind, cross-over study. One hour after felodipine 5 mg, echocardiographic ejection fraction (%), cardiac index (thermodilution-ml/min/m2), and pulmonary wedge pressure (mm Hg) significantly changed (from 21 +/- 2 to 26 +/- 2, 2350 +/- 150 to 2790 +/- 160, 24 +/- 4 to 17 +/- 4) while they remained steady after felodipine 10 mg. The greatest stroke index increases were associated with felodipine 5 mg in 12 patients and 10 mg in 1 patient. Therefore we evaluated (open study) the long-term (2 months- 1 year) clinical and hemodynamic efficacy following the treatment with the acutely most effective dose (twice daily). After 2 months ejection fraction, cardiac index and pulmonary wedge pressure were respectively 24 +/- 2, 2550 +/- 150, and 18 +/- 4 (12 hours after the last drug administration, n = 11, P less than 0.02 from baseline). These parameters further increased one to two hours after the following administration of felodipine. Clinical improvement (reduction of 1 functional class, according to the New York Heart Association) was observed in 8/13 patients. These 8 patients participated to the one year follow-up. In 5 patients follow-up was interrupted because of acute cardiovascular events. However, before study interruption (5 patients) or ending (3 patients) clinical status did not worsen and ejection fraction remained higher than in the pretreatment period. Therefore, low dose felodipine might be used in the treatment of congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1991673     DOI: 10.1016/0167-5273(91)90128-c

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  2 in total

1.  Effects of felodipine on the ischemic heart: insight into the mechanism of cytoprotection.

Authors:  R Ferrari; A Cargnoni; P Bernocchi; G Gaia; M Benigno; E Pasini; P Pedersini; C Ceconi
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 2.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.